https://clinical-chaos-dsv.pages.dev/ Open funding calls in clinical research, clinical engineering and rehabilitation, checked on the official text. en https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-383 GG-PAR-25-383 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports translational activities and clinical studies to accelerate the development of medical devices for disorders within the missions of participating NIH institutes and centers. Funding covers prototype implementation, non-clinical testing, design verification, and clinical studies. Eligible applicants include higher education institutions, non-profits, for-profit organizations, and foreign organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 28 Jan 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/358823 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-01-DISEASE-07 EU-HORIZON-HLTH-2027-01-DISEASE-07 Sat, 24 Oct 2026 08:00:00 +0000 This topic supports the development of prophylactic and therapeutic monoclonal antibody candidates targeting specific viruses, including Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, or Chikungunya. Funded activities include in-vitro characterisation, in-vivo animal testing, GMP-compliant batch production, and first-in-human clinical safety trials. Proposals should advance existing candidates, with the participation of start-ups, SMEs, and entities from endemic third countries encouraged. Programme: Horizon Europe – Cluster 1: Health. Eligible countries: EU Member States and associated countries. Deadline: 17 Feb 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-07 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-01-ENVHLTH-02 EU-HORIZON-HLTH-2027-01-ENVHLTH-02 Sat, 24 Oct 2026 08:00:00 +0000 This call supports research strengthening the use of the exposome approach to study global exposures and generate evidence on their health implications, focusing on integrating climate-related factors into exposome research. Funded activities include incorporating multiple climate exposures into exposomics studies, monitoring exposome changes resulting from climate pressures, advanced data analytics, and identifying exposome biomarkers. Collaborative multiscale and multidisciplinary projects involving social sciences and humanities can apply. Programme: Horizon Europe – Cluster 1: Health. Eligible countries: EU Member States and associated countries. Deadline: 17 Feb 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-ENVHLTH-02 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-01-CARE-02 EU-HORIZON-HLTH-2027-01-CARE-02 Sat, 24 Oct 2026 08:00:00 +0000 This call supports research to reduce the incidence and severity of Adverse Drug Reactions (ADRs) resulting from multiple medications. Funded activities include leveraging pharmacogenomics, pharmacokinetics, and biomarkers for patient stratification, alongside integrating health technologies such as artificial intelligence and electronic health records into clinical practice. Proposals should also address clinical utility, guidelines, and regulatory implementation. Interdisciplinary consortia and clinical researchers, with the encouraged participation of SMEs and start-ups, can apply. Programme: Horizon Europe – Cluster 1: Health. Eligible countries: EU Member States and associated countries. Deadline: 17 Feb 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-CARE-02 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-02-TOOL-01-two-stage EU-HORIZON-HLTH-2027-02-TOOL-01-two-stage Sat, 24 Oct 2026 08:00:00 +0000 This call supports collaborative research and innovation projects aiming to develop and clinically validate multimodal predictive biomarkers for chronic non-communicable diseases, excluding cancer. Projects must leverage established artificial intelligence methodologies to integrate clinical data, candidate biomarkers, and real-world data, ensuring trustworthy AI and GDPR compliance. Eligible applicants include multidisciplinary consortia of research organizations, universities, and SMEs, with the goal of advancing personalized medicine and improving healthcare outcomes. Programme: Horizon Europe. Eligible countries: EU Member States and associated countries. Who can lead: Entities in the EU/EFTA and/or Associated Countries leading prospective clinical studies.. Stage 1 deadline: 17 Feb 2027 (two-stage call). Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-02-TOOL-01-two-stage https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-01-DISEASE-05 EU-HORIZON-HLTH-2027-01-DISEASE-05 Sat, 24 Oct 2026 08:00:00 +0000 This topic supports the development of novel or existing antiviral candidates targeting specific emerging and re-emerging viruses with epidemic potential, excluding antibodies. Funded activities include candidate discovery, structure-activity relationship optimization, in-vitro and in-vivo characterization, GMP manufacturing, and first-in-human clinical safety studies. Consortia are expected to engage with regulatory bodies, leverage research infrastructures, and encourage the participation of start-ups, SMEs, and entities from endemic third countries. Programme: Horizon Europe – Cluster 1: Health. Eligible countries: EU Member States and associated countries. Deadline: 17 Feb 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-05 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-MH-26-140 GG-RFA-MH-26-140 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports the development of next-generation sensor technologies and bioelectronic devices that synchronize with brain recordings to model organismal and human behavior. It aims to foster multidisciplinary collaborations among engineers and behavioral scientists to create reliable, compact, real-time sensing tools. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and international foreign organizations. Programme: National Institutes of Health (NIH). Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 15 Jun 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356811 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-24-325 GG-PAR-24-325 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies addressing important biomedical problems. The goal is to establish robust, well-characterized solutions fulfilling unmet needs within five to ten years. Eligible applicant organizations include higher education institutions, non-profits, for-profit organizations, and foreign entities. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 27 Jan 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357019 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-179 GG-PAR-25-179 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports confirmatory efficacy testing of non-pharmacological and, under certain conditions, pharmacological preventive and therapeutic interventions for mental disorders in adults and children. Projects must employ an experimental therapeutics approach to examine mechanisms of action, target engagement, and clinical outcomes. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI is invited to work with their organization. Next deadline: 17 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357423 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-183 GG-PAR-25-183 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports early-stage clinical trial applications evaluating novel pharmacologic or neuromodulatory device-based interventions for mental disorders. The aim is to test target engagement and mechanism of action alongside clinical or functional outcomes in pediatric, adult, and geriatric populations. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign entities. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 17 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357430 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-177 GG-PAR-25-177 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports well-powered clinical trials to evaluate the effectiveness and implementation of optimized mental health prevention and treatment interventions in real-world settings. Projects must examine implementation challenges, clinical impact, and at least one mechanism of action. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, local and state governments, tribal governments, and foreign organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 17 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357421 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-178 GG-PAR-25-178 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports pilot hybrid effectiveness-implementation research to optimize preventive and therapeutic mental health interventions and related implementation strategies in accessible settings such as routine care, schools, communities, or online platforms. Proposed projects must test intervention effectiveness, implementation factors, and mechanisms of action. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Clinical trials are required. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 17 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357422 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-285 GG-PAR-25-285 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports milestone-driven feasibility and infrastructure development research followed by a well-powered clinical trial to test the effectiveness of system interventions or strategies. The aim is to improve the organization, delivery, coordination, and outcomes of mental health care. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, local and state governments, tribal governments, and non-domestic foreign organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 17 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357434 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-AI-28-015 GG-RFA-AI-28-015 Sat, 24 Oct 2026 08:00:00 +0000 The National Institute of Allergy and Infectious Diseases seeks to advance HIV research by funding effectiveness trials and implementation science studies in real-world settings. The program supports combined efficacy-effectiveness trials, pragmatic trials, and hybrid studies focusing on HIV prevention, treatment, coinfections, and comorbidities across various populations and points of care. Eligible applicants include domestic and foreign public and private non-profit and for-profit organizations, as well as governmental entities. Programme: NIH – US National Institutes of Health. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/363948 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-103 GG-PAR-25-103 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports well-planned clinical trials across the cancer prevention and control spectrum, aiming to improve interception, screening, early detection, healthcare delivery, and survivorship outcomes. It funds preparatory activities and pilot feasibility studies to address information gaps in study population, accrual, and operational risks prior to a full-scale clinical trial. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 25 Oct 2026 (new applications). Official call: https://www.grants.gov/search-results-detail/356978 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-HD-28-002 GG-RFA-HD-28-002 Sat, 24 Oct 2026 08:00:00 +0000 This call funds the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource-Constrained Settings Implementation Science Network (PATC3H-IN). It supports implementation science research in low- and middle-income countries to develop scalable HIV prevention and treatment models for adolescents, improving care outcomes globally and providing evidence applicable to U.S. populations. Eligible applicants include domestic and foreign institutions, non-profits, tribal governments, and international entities. Programme: NIH – US National Institutes of Health. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/364127 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-145 GG-PAR-25-145 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity promotes research studies addressing chronic or delayed adverse sequelae resulting from cancer therapies. It supports basic, translational, and clinical research projects to identify mechanisms of therapy-induced adverse sequelae, clinically characterize them, and translate findings into preventive or therapeutic approaches. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Projects can include clinical trials. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 5 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357015 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-136 GG-PAR-25-136 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity seeks innovative research projects to test and optimize strategies for digital mental health interventions. It supports the development of digital health test beds utilizing established platforms to refine evidence-based interventions and conduct rigorous clinical trials. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations, aiming to improve mental health care reach, efficiency, and clinical effectiveness. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 5 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357034 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-207 GG-PAR-25-207 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity seeks research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. The call supports clinical trials designed to establish effectiveness and test mechanisms of action, mediators, and moderators of post-acute phase interventions. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and non-domestic foreign organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 5 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356924 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PA-25-172 GG-PA-25-172 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity encourages research applications in cancer control and population sciences. It aims to support novel scientific ideas advancing statistical and analytic methods, epidemiology, cancer survivorship, behavioral interventions, healthcare delivery, digital health, and implementation science. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and foreign organizations. Clinical trials are optional. Awards are limited to $250,000 in direct costs per year with a maximum project period of five years. Programme: National Institutes of Health (NIH) / National Cancer Institute (NCI). Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 5 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357030 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-358 GG-PAR-25-358 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports researchers in planning large-scale clinical vision research projects, including randomized clinical trials and epidemiological studies. It funds the development of study protocols, manuals of procedures, and preliminary studies to assess recruitment potential. Funds cannot be used to test therapeutic interventions. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. The goal is to ensure rigorous preparation for future clinical studies. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/358118 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PA-25-306 GG-PA-25-306 Sat, 24 Oct 2026 08:00:00 +0000 The National Institutes of Health funding opportunity supports exploratory and developmental research projects during their early and conceptual stages to drive biomedical, behavioral, or clinical breakthroughs. Funded activities include high-risk, innovative studies, novel techniques, and methodologies, and applicants are strictly required to propose at least one clinical trial. Eligible applicant organizations include higher education institutions, non-profits, for-profit organizations, governments, and non-domestic foreign entities. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357809 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-321 GG-PAR-25-321 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity encourages exploratory and developmental bioengineering research grant applications to demonstrate feasibility and utility of new capabilities or improvements in biomedical, pre-clinical, or clinical research and clinical care. The initiative supports research aiming to identify cancer risks, causes, and prevention interventions. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and foreign organizations. The maximum project period is two years with direct costs not exceeding $275,000. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357627 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-346 GG-PAR-25-346 Sat, 24 Oct 2026 08:00:00 +0000 This National Institutes of Health funding opportunity encourages exploratory and developmental bioengineering research grant applications to demonstrate the feasibility and potential utility of new capabilities or improvements in biomedical, pre-clinical, or clinical research and care delivery. Funded activities include developing novel tools, technologies, or methods without clinical trials. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Programme: National Institutes of Health (NIH). Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357651 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-144 GG-PAR-25-144 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports research to identify, develop, and test strategies for overcoming barriers to the adoption, integration, sustainability, and scale-up of evidence-based interventions, practices, and policies in health. It aims to bridge the gap between research, practice, and policy by funding rigorous studies, including clinical trials where appropriate, conducted by higher education institutions, nonprofits, governments, and foreign organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Next deadline: 5 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356893 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-143 GG-PAR-25-143 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports exploratory and developmental studies (R21 mechanism) that identify, develop, or test strategies to improve the adoption, scale-up, integration, and sustainability of evidence-based health interventions, policies, and practices. It also encourages research on de-implementing ineffective practices and advancing research methods. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign organizations globally. Programme: National Institutes of Health (NIH). Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356920 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-233 GG-PAR-25-233 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity from the National Institutes of Health supports small research grants (R03) to identify, develop, or test strategies for overcoming barriers to the adoption, integration, sustainability, and scale-up of evidence-based health interventions and policies. Studies advancing dissemination and implementation research methods, measures, or de-implementation of ineffective practices are encouraged. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Clinical trials are not allowed. Programme: National Institutes of Health (NIH). Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356907 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-446 GG-PAR-25-446 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports preclinical and clinical research to discover and develop interventions preventing and treating substance use disorders and overdose. Funded activities include pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions aimed at advancing candidates toward regulatory approval or clinical adoption. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and non-domestic foreign entities. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 22 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/358937 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-011 GG-PAR-27-011 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports investigator-initiated single-site clinical trials relevant to the NHLBI mission, including efficacy, comparative effectiveness, pragmatic, and implementation science trials. It utilizes a bi-phasic, milestone-driven R61/R33 mechanism to fund both the planning and execution phases. Eligible applicants include domestic and foreign organizations, though restrictions apply regarding international subawards. The multiple PD/PI model is strongly encouraged to bring together necessary expertise. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Multiple PD/PI model strongly encouraged; applicants should include expertise in biostatistics, clinical trial design, and coordination.. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/358850 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-AI-27-018 GG-RFA-AI-27-018 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports implementation research to improve the uptake, implementation, sustainment, and scale of evidence-based HIV prevention, treatment, and care interventions in communities in the U.S. significantly impacted by HIV. Projects should be large in scale, encompassing single-site, multi-site, or comparative studies with high public health impact. Eligible applicants include domestic and foreign institutions, government agencies, tribal entities, and non-profit or for-profit organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/360873 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-064 GG-PAR-27-064 Sat, 24 Oct 2026 08:00:00 +0000 This notice of funding opportunity supports the implementation of investigator-initiated, milestone-driven clinical trials requiring enhanced oversight, including mechanistic studies where applicable. Funding is available for clinical trials lasting up to five years, or extended trials of six to seven years. Eligible applicants include domestic and foreign higher education institutions, nonprofits, for-profit organizations, governments, and small businesses. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/359859 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-072 GG-PAR-27-072 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity encourages multidisciplinary collaborations between life and physical sciences to apply bioengineering approaches to biomedical problems and accelerate the adoption of promising tools, methods, and techniques in basic, translational, or clinical science. It supports small teams conducting design-directed, developmental, discovery-driven, or hypothesis-driven research, including clinical trials testing functionality or validating performance. Domestic and foreign organizations are eligible to apply. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/360543 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-090 GG-PAR-27-090 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity invites R01 applications proposing research on palliative care across the lifespan for persons with serious illnesses and their care partners. It supports efficacy, effectiveness, and implementation clinical trials, as well as health services and observational studies. Funded projects will join the ASCENT Consortium. Eligible applicants include domestic and foreign institutions, educational entities, nonprofits, and government organizations. Stage I pilot interventions are excluded. Programme: NIH – US National Institutes of Health. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/360675 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-01-DISEASE-08 EU-HORIZON-HLTH-2027-01-DISEASE-08 Sat, 24 Oct 2026 08:00:00 +0000 This funding call supports the development of innovative antibacterial and antifungal agents, including antibody-based therapies, targeting specific drug-resistant pathogens to combat antimicrobial resistance. Funded activities include in-vivo testing, GMP batch production, and human clinical safety and efficacy studies. Eligible applicants include consortia of legal entities, with participation encouraged for startups and SMEs, aiming to accelerate novel candidates into human clinical trials and strengthen the EU research ecosystem. Programme: Horizon Europe – Cluster 1: Health. Eligible countries: EU Member States and associated countries. Deadline: 17 Feb 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-08 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-03-TOOL-04 EU-HORIZON-HLTH-2027-03-TOOL-04 Sat, 24 Oct 2026 08:00:00 +0000 This call supports the development and clinical validation of multi-organ, multi-scale Virtual Human Twin models to improve prevention and diagnosis in high disease burden areas. Projects must design dynamic computational models, integrate them with healthcare workflows, and demonstrate clinical and cost-effectiveness. Consortia must be multidisciplinary and involve end-users, while contributing to the European VHT Initiative. Programme: Horizon Europe. Eligible countries: EU Member States and associated countries. Deadline: 16 Sep 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-03-TOOL-04 https://clinical-chaos-dsv.pages.dev/calls#c-WEB-eb079c6b7229 WEB-eb079c6b7229 Sat, 24 Oct 2026 08:00:00 +0000 This call appears to relate to AssistiveTech2026 from the ALS Association, aimed at supporting innovative assistive technologies for people living with amyotrophic lateral sclerosis. However, the provided official text consists entirely of unparsed binary PDF stream data. As a result, specific objectives, eligible applicant categories, project budgets, and application requirements cannot be verified or confirmed directly from the official text. Programme: ALS Association. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: http://www.als.org/AssistiveTech2026 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526VRPTRA GG-HT942526VRPTRA Sat, 24 Oct 2026 08:00:00 +0000 The fiscal year 2026 Vision Research Program Translational Research Award supports translational research that transforms a promising discovery into new drugs, devices, or clinical practice guidelines ready for definitive testing in clinical trials. It funds preclinical studies, clinical research, or pilot clinical trials. Independent investigators affiliated with eligible organizations worldwide can apply. Programme: Defense Health Agency Vision Research Program. Eligible countries: Any country. Who can lead: Independent investigators affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citiz. Deadline: 12 Nov 2026. Official call: https://www.grants.gov/search-results-detail/362186 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526JWMRPMMRDA GG-HT942526JWMRPMMRDA Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports the logical continuation of previous Department of War-funded research and development efforts to address high-priority military medical requirements. It funds late-stage preclinical studies, technology development, translational research, and clinical trials addressing specific focus areas. Eligible applicants include domestic and foreign organizations, both for-profit and nonprofit, provided they have previously received Department of War core or Congressional Special Interest funding. Programme: Defense Health Agency Research and Development, Joint Warfighter Medical Research Program. Eligible countries: Any country. Who can lead: Independent investigators affiliated with an eligible organization, regardless of ethnicity, nationality or citizenship status.. Stage 1 deadline: 16 Nov 2026 (two-stage call). Official call: https://www.grants.gov/search-results-detail/362857 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526ORPCRA GG-HT942526ORPCRA Sat, 24 Oct 2026 08:00:00 +0000 The fiscal year 2026 Orthopaedic Research Program Clinical Research Award seeks clinical research and trials evaluating orthopaedic-specific factors and interventions. It aims to generate evidence optimizing patient outcomes, informing clinical care, and benefiting Service Members, Veterans, and the general public. Projects must address specific focus areas across two research levels, supporting either clinical studies or clinical trials up to four years. Programme: CDMRP – Orthopaedic Research Program (ORP). Eligible countries: Any country. Who can lead: Independent investigators at all career levels affiliated with an eligible organization, regardless of ethnicity, nationality or citizenship status.. Stage 1 deadline: 18 Nov 2026 (two-stage call). Official call: https://www.grants.gov/search-results-detail/362524 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526TERPCTA GG-HT942526TERPCTA Sat, 24 Oct 2026 08:00:00 +0000 The Toxic Exposures Research Program Clinical Trial Award supports the advancement, execution, and analysis of clinical trials addressing symptoms, diseases, or conditions resulting from military-related toxic exposures. Funded projects range from small proof-of-concept trials to large-scale efficacy studies. Eligible applicants include extramural and intramural organizations worldwide, including foreign and domestic, for-profit and nonprofit entities. Programme: CDMRP – Toxic Exposures Research Program (TERP). Eligible countries: Any country. Who can lead: Independent investigators at all career levels may be named as Principal Investigator. Mentored positions are excluded.. Stage 1 deadline: 19 Nov 2026 (two-stage call). Official call: https://www.grants.gov/search-results-detail/362302 https://clinical-chaos-dsv.pages.dev/calls#c-GG-FOR-FD-24-003 GG-FOR-FD-24-003 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity aims to develop and test an artificial intelligence- or machine learning-based algorithmic real-world data model for post-market surveillance of complex generic drug products compared to reference listed drugs. Funded projects will monitor therapeutic equivalence and inform regulatory decision-making. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, small businesses, and government entities. Clinical trials are not allowed under this cooperative agreement mechanism. Programme: Food and Drug Administration. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/351125 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526BCRPCREA2 GG-HT942526BCRPCREA2 Sat, 24 Oct 2026 08:00:00 +0000 The fiscal year 2026 Breast Cancer Research Program Clinical Research Extension Award supports research that extends data collection, follow-up, and analysis of breast cancer clinical studies to increase their clinically relevant impact. It funds deeper molecular analysis, correlative studies, biomarker validation, or patient follow-up. Independent investigators affiliated with any eligible organization worldwide can apply, and the research team must include consumer advocates and meet specific programmatic challenges. Programme: CDMRP – Breast Cancer Research Program (BCRP). Eligible countries: Any country. Who can lead: Independent investigators affiliated with an eligible organization are eligible to be named PI, regardless of ethnicity, nationality or citizenship status.. Deadline: 18 Nov 2026. Official call: https://www.grants.gov/search-results-detail/363671 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526ORPARA GG-HT942526ORPARA Sat, 24 Oct 2026 08:00:00 +0000 The Orthopaedic Research Program Applied Research Award seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat or service-related activities. The programme funds preclinical applied research projects addressing specific focus areas like battlefield infections, composite tissue regeneration, and return-to-duty strategies. Independent investigators at all career levels affiliated with eligible domestic and foreign organizations can apply. Programme: CDMRP – The Orthopaedic Research Program (ORP). Eligible countries: Any country. Who can lead: Independent investigators at all career levels affiliated with an eligible organization are eligible, regardless of ethnicity, nationality or citizenship status. Stage 1 deadline: 18 Nov 2026 (two-stage call). Official call: https://www.grants.gov/search-results-detail/362520 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-045 GG-PAR-27-045 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports a phased mechanistic clinical research program focusing on understudied biological mechanisms that drive joint pain. Funded projects will identify and validate multi-tissue mechanisms underlying joint pain and test non-pharmacologic or multimodal interventions targeting these mechanisms, advancing safe and non-addictive approaches to chronic pain management. Eligible applicants include domestic U.S. organizations such as higher education institutions, nonprofits, local and state governments, and businesses. Programme: NIH HEAL Initiative. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/361304 https://clinical-chaos-dsv.pages.dev/calls#c-WEB-927805bf0a8f WEB-927805bf0a8f Sat, 24 Oct 2026 08:00:00 +0000 This fellowship scheme offers postdoctoral research funding for early-career researchers with one to three years of postdoctoral experience to develop projects focused on healthy aging and related topics. The initiative funds up to four awards worth up to 350,000 pounds each for a duration of three years full-time or up to six years part-time. Eligible lead applicants are early-career researchers hosted by approved academic institutions. Programme: Dunhill Medical Trust. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://vivensafoundation.org.uk/wp-content/uploads/2026/03/26-03-Early-Career-Postdoctoral-Fellowship-Scheme-Guidelines.pdf https://clinical-chaos-dsv.pages.dev/calls#c-WEB-39a5e4093d78 WEB-39a5e4093d78 Sat, 24 Oct 2026 08:00:00 +0000 The Turnbull-Tator Award, supported by the Barbara Turnbull Foundation for Spinal Cord Research and the Brain Canada Foundation, funds research in the field of spinal cord injury and brain injury, including concussions. The initiative aims to support discoveries that promote repair, regeneration, and functional recovery of the damaged nervous system, improving the quality of life for individuals with neurotrauma. Programme: Brain Canada. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://braincanada.ca/files/2026-turnbull-tator-award-request-for-applications.pdf https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-AT-27-002 GG-RFA-AT-27-002 Sat, 24 Oct 2026 08:00:00 +0000 The NIH Blueprint for Neuroscience Research plans to fund an interdisciplinary Research Network to guide and integrate foundational research on human consciousness. Rather than supporting discrete research projects, the network will focus on capacity building, standardizing definitions, developing coordination frameworks, and providing interdisciplinary training opportunities. Eligible applicants include higher education institutions, nonprofits, small businesses, for-profit organizations, tribal organizations, and various local, state, and federal governmental bodies. Programme: NIH Blueprint for Neuroscience Research. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/362097 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HHS-2027-ACL-NIDILRR-DPTB-0311 GG-HHS-2027-ACL-NIDILRR-DPTB-0311 Sat, 24 Oct 2026 08:00:00 +0000 The Traumatic Brain Injury Model Systems Centers funding opportunity aims to conduct research that contributes to the development of and access to evidence-based TBI rehabilitation. Funded centers generate new knowledge to improve outcomes in health and function, community living and participation, and employment by conducting site-specific and collaborative research while contributing to a longitudinal database. Eligible applicants include states, public or private agencies and organizations, IHEs, and Indian tribes. Programme: Administration for Community Living. Eligible countries: United States only. Who can lead: States, public or private agencies, organizations, IHEs, and Indian tribes providing a multidisciplinary continuum of care for people with TBI.. Deadline: 1 Apr 2027. Official call: https://www.grants.gov/search-results-detail/363970 https://clinical-chaos-dsv.pages.dev/calls#c-WEB-420f4b1625e7 WEB-420f4b1625e7 Sat, 24 Oct 2026 08:00:00 +0000 The Dunhill Medical Trust fellowship scheme supports mid- to senior-career postdoctoral researchers aiming to become future leaders in ageing research. Two co-funded positions are offered in partnership with a host academic institution that must commit to providing a permanent academic position upon completion. Funding covers up to 500,000 pounds for 3 to 5 years of full-time research, with progressive cost-sharing by the university. Only one applicant is permitted per department or faculty. Programme: Dunhill Medical Trust. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://vivensafoundation.org.uk/wp-content/uploads/2026/03/26-03-Proleptic-Postdoctoral-Fellowship-Scheme-Guidelines.pdf https://clinical-chaos-dsv.pages.dev/calls#c-WEB-3e0abf79b1c9 WEB-3e0abf79b1c9 Sat, 24 Oct 2026 08:00:00 +0000 The Hand in Hand Research Grant supports early-stage research projects focused on hand and upper extremity therapy with strong community involvement. The funding aims to lay the groundwork for future large-scale studies, improving clinical outcomes and promoting evidence-based practice. Research priorities include health disparities, comparative effectiveness, clinical outcomes validation, and the use of orthoses and biophysical agents. Eligible applicants are researchers affiliated with U.S. institutions, with a maximum funding of 50,000 dollars for one year. Programme: American Occupational Therapy Foundation. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://www.aotf.org/wp-content/uploads/2026/08/HiHRG_-Award-Guidelines-2026-2027.pdf https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-AI-27-002 GG-RFA-AI-27-002 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity solicits applications for the Infectious Diseases Clinical Trials Network (IDCTN), which supports the evaluation of interventions for emerging and chronic infections through Clinical Trial Evaluation Units and a Network Coordination Center. The network designs and implements clinical studies while advancing early-career investigators. Eligible applicants include domestic United States organizations such as higher education institutions, nonprofits, governments, and businesses. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/360875 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-AI-27-005 GG-RFA-AI-27-005 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports a Clinical Research Network on Antimicrobial Resistance to design, implement, and manage pivotal clinical research through four specialized centers focusing on scientific leadership, clinical operations, laboratory work, and statistics/data coordination. Eligible applicants include domestic U.S. organizations such as higher education institutions, nonprofits, governments, and businesses, while foreign organizations and foreign subawards are strictly excluded. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/361065 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-141 GG-PAR-25-141 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity solicits cooperative agreement applications for the implementation of investigator-initiated, single or multi-site interventional clinical trials in rheumatic, musculoskeletal, and skin diseases. The mechanism features a two-phase, milestone-driven structure consisting of a start-up planning phase (UG3) and a full clinical trial execution phase (UH3). Eligible applicants include domestic higher education institutions, non-profits, for-profit organizations, and local or state governments. Programme: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 2 Nov 2026 (new applications). Official call: https://www.grants.gov/search-results-detail/357606 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-032 GG-PAR-25-032 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports pilot and preliminary studies using the R34 mechanism to inform the planning, design, and feasibility of future Phase II-IV clinical trials within the mission of the National Heart, Lung, and Blood Institute (NHLBI). Funded projects address critical information gaps related to interventions for heart, lung, blood, or sleep disorders. Eligible applicants include higher education institutions, nonprofits, local and state governments, and for-profit organizations based in the U.S. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357800 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-008 GG-PAR-27-008 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity from the National Institute of Mental Health will support Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers. Funded interdisciplinary centers will conduct high-impact, practice-based research to rapidly develop, test, and refine novel interventions that improve mental health care access, quality, and outcomes. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and tribal organizations. Programme: NIH – US National Institutes of Health. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/361521 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-AI-28-007 GG-RFA-AI-28-007 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports the Childhood Asthma in Urban Settings Clinical Research Network to advance multi-site clinical studies and trials on asthma prevention and treatment in economically disadvantaged pediatric populations. Funded research includes developing prevention strategies, testing new treatment targets, and identifying disease endotypes using systems biology. Eligible applicants include higher education institutions, nonprofits, small businesses, for-profit organizations, tribal and local governments, and federal agencies. Programme: Childhood Asthma in Urban Settings Clinical Research Network (CAUSE). Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/362950 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-180 GG-PAR-25-180 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports milestone-driven early stage clinical trials, including first-in-human, Phase Ib, Phase II/PoC, and early feasibility studies for novel investigational drugs or neuromodulatory devices addressing psychiatric disorders. The goal is to de-risk these interventions to attract further clinical development funding. Eligible applicants include higher education institutions, non-profits, for-profit organizations, and government entities based in the United States. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 17 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357424 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-HL-26-019 GG-RFA-HL-26-019 Sat, 24 Oct 2026 08:00:00 +0000 This funding call provides early stage translational support to develop and test device prototype designs, identify diagnostic disease targets, develop associated assays, and build research tools for treating heart, lung, blood, and sleep diseases and disorders. Structured as an R61/R33 phased award, it funds prototype design and initial testing in the first phase, followed by further optimization and validation. Eligible applicants include domestic higher education institutions, non-profits, for-profit organizations, and governments. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 11 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357339 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-HL-26-020 GG-RFA-HL-26-020 Sat, 24 Oct 2026 08:00:00 +0000 This National Institutes of Health funding opportunity provides early-stage translational support for prototype testing, design modification, diagnostic assay development, and research tools targeting heart, lung, blood, and sleep diseases. The goal is to advance innovations toward preclinical testing or external development. Eligible applicants include domestic higher education institutions, non-profits, for-profit organizations, and governments. Foreign organizations are ineligible. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 11 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357340 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-188 GG-PAR-25-188 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity provides support for the planning and implementation of behavioral and biopsychosocial intervention studies relevant to dental, oral, and craniofacial health that meet the NIH definition of a clinical trial. It uses a phased cooperative agreement supporting a milestone-driven planning phase followed by a clinical trial implementation phase. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and local or state governments based in the United States. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 8 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357462 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-057 GG-PAR-25-057 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity supports phased, milestone-driven cooperative agreement applications to plan and implement clinical trials within the NIDCR mission. It funds studies testing drugs, biologics, devices, or procedures to improve dental, oral, or craniofacial health through a one-year UG3 planning phase and up to five years of UH3 implementation. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and governments based in the United States. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 8 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356815 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-24-273 GG-PAR-24-273 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity aims to advance innovative multi-level healthcare research for older adults from populations experiencing health disparities. It supports research to improve screening and clinical care guidelines, enhance shared decision-making between clinicians, patients, and caregivers, and identify effective care coordination strategies. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, local and state governments, and tribal governments based in the United States. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 5 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356236 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PA-25-168 GG-PA-25-168 Sat, 24 Oct 2026 08:00:00 +0000 The National Institutes of Health awards Institutional Research Training Grants (T32) to eligible domestic institutions to develop or enhance predoctoral and postdoctoral research training. The goal is to ensure a highly trained biomedical, behavioral, and clinical research workforce. Programs must incorporate engaging didactic, research, and career development elements. Only domestic U.S. institutions may apply, and foreign entities or foreign components are explicitly excluded from participating as applicants. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research training program as the Training Program Director/PI.. Next deadline: 25 Jan 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357140 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-450 GG-PAR-25-450 Sat, 24 Oct 2026 08:00:00 +0000 This call invites researchers to submit applications for clinical projects addressing critical needs for clinical trial readiness in rare diseases. It aims to facilitate rare diseases research by enabling the movement of candidate therapeutics or diagnostics toward clinical trials through the development of rigorous biomarkers, clinical outcome assessment measures, or natural history studies. Eligible applicants include various U.S. institutional types. Clinical trials are not allowed. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 17 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/359645 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-DC-27-003 GG-RFA-DC-27-003 Sat, 24 Oct 2026 08:00:00 +0000 This funding opportunity from the National Institutes of Health supports the development and adaptation of transformative in vivo high-resolution, high-specificity imaging technologies for the human olfactory system across scales. Projects must leverage advanced non-invasive or minimally invasive imaging to visualize peripheral and central olfactory targets. Multidisciplinary teams combining expertise in olfaction, biomedical imaging, biochemistry, bioengineering, and biophysics are encouraged. Non-U.S. entities and foreign components are not eligible to apply. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/359696 https://clinical-chaos-dsv.pages.dev/calls#c-WEB-cc0af2e5cfce WEB-cc0af2e5cfce Sat, 24 Oct 2026 08:00:00 +0000 MS Australia offers a range of project grants, fellowships, scholarships, and travel awards to support research relevant to multiple sclerosis. The funding aims to advance knowledge, treatment, or management of MS. Eligible applicants must be Australian or New Zealand citizens or permanent residents. Programme: MS Australia Grant Program. Eligible countries: Australia and New Zealand only. Who can lead: Australian or New Zealand citizen or permanent resident.. Deadline: see the official call. Official call: https://grants.msaustralia.org.au/ https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-053 GG-PAR-25-053 Fri, 23 Oct 2026 08:00:00 +0000 This National Institutes of Health funding opportunity encourages researchers to pursue translational activities and small clinical studies to advance the development of low-risk therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. Funded activities include clinical prototype implementation, non-clinical safety testing, design verification, and subsequent small clinical studies. Eligible applicants include domestic and foreign higher education institutions, nonprofits, for-profit organizations, and governments. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 28 Jan 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356903 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-DK-28-116 GG-RFA-DK-28-116 Fri, 23 Oct 2026 08:00:00 +0000 This funding opportunity forecast supports milestone-driven research combining multimodal human pancreas and clinical datasets to understand how biological processes interact in type 1 diabetes (T1D). The initiative funds the development and testing of multimodal artificial intelligence models, AI-enabled research workflows, data integration methods, and privacy-preserving synthetic datasets. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, state and local governments, and non-domestic (foreign) entities. Clinical trials are not allowed. Programme: NIH – US National Institutes of Health. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/363678 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-BRIDGING-2027-06-02 EU-HORIZON-BRIDGING-2027-06-02 Fri, 23 Oct 2026 08:00:00 +0000 This call aims to bridge the structural gap between Horizon research outcomes and market-oriented support mechanisms. It funds consortia of knowledge intermediaries to scout promising innovations, launch competitive calls for third-party financial support, and provide expert mentorship, validation, and valorisation services. Applicants must be entities forming consortia acting as knowledge intermediaries within innovation ecosystems. Programme: Horizon Europe. Eligible countries: EU Member States and associated countries. Deadline: 16 Feb 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-BRIDGING-2027-06-02 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-125 GG-PAR-27-125 Fri, 23 Oct 2026 08:00:00 +0000 This upcoming NIH funding opportunity will solicit applications to develop and implement investigator-initiated multi-site clinical trials, including efficacy, effectiveness, pragmatic, or implementation research, as well as complex virtual trials. The scheme supports projects through a bi-phasic mechanism consisting of a start-up phase of up to two years and a trial implementation phase of up to five years. Higher education institutions, non-profits, for-profit businesses, and non-domestic foreign entities will be eligible to apply. Programme: NIH – US National Institutes of Health. Eligible countries: Coming soon: published with the full call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/363025 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-01-DISEASE-06 EU-HORIZON-HLTH-2027-01-DISEASE-06 Fri, 23 Oct 2026 08:00:00 +0000 This call aims to support the development of prophylactic and therapeutic monoclonal antibody candidates targeting specific Flaviviruses such as Dengue, Tick-borne Encephalitis, Japanese Encephalitis, West Nile Fever, Yellow Fever, and Zika. Funded activities include in-vitro and in-vivo testing, GMP batch production, and first-in-human clinical safety studies. Eligible applicants include research entities, universities, start-ups, and SMEs from EU member states and associated countries forming consortia. Programme: Horizon Europe – Cluster 1: Health. Eligible countries: EU Member States and associated countries. Deadline: 17 Feb 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-06 https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-JU-EUROHPC-2026-QML-07-01 EU-HORIZON-JU-EUROHPC-2026-QML-07-01 Fri, 23 Oct 2026 08:00:00 +0000 This EuroHPC JU call under Horizon Europe supports the development and validation of advanced quantum machine learning (QML) models and algorithms. The goal is to integrate quantum computing into data processing workflows to overcome computational bottlenecks, with applications in sectors including healthcare, life sciences, and image-based medical diagnosis. Research centers, universities, and technology companies can participate to strengthen European leadership in quantum computing and trustworthy AI. Programme: Horizon Europe – HORIZON JU Research and Innovation Actions. Eligible countries: EU Member States and associated countries. Who can lead: Research centers, universities, industries, SMEs and technology startups, typically requiring a consortium of at least 3 independent entities from 3 EU/associat. Deadline: 28 Jan 2027. Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-JU-EUROHPC-2026-QML-07-01 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HHS-2027-ACL-NIDILRR-ARCP-0300 GG-HHS-2027-ACL-NIDILRR-ARCP-0300 Fri, 23 Oct 2026 08:00:00 +0000 This opportunity under the Advanced Rehabilitation Research Training (ARRT) Program aims to provide advanced multidisciplinary research training to individuals with doctorates or similar advanced degrees, including researchers with disabilities. Funded projects must focus on community living and participation outcomes for people with disabilities. A single grant with a 36-month project period will be awarded. Public, state-controlled, and private institutions of higher education are eligible to apply; foreign entities are excluded. Programme: Advanced Rehabilitation Research Training (ARRT) Program. Eligible countries: United States only. Deadline: 7 Dec 2026. Official call: https://www.grants.gov/search-results-detail/363963 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-OH-26-001 GG-RFA-OH-26-001 Fri, 23 Oct 2026 08:00:00 +0000 The National Institute for Occupational Safety and Health (NIOSH) seeks research project applications to optimize member care, diagnose and treat health conditions related to the September 11, 2001 terrorist attacks, and expand scientific knowledge on physical and mental health impacts. Eligible applicants include domestic public and private non-profit organizations, higher education institutions, local and state governments, and small businesses. Programme: Centers for Disease Control and Prevention - ERA. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Anyone who has the skills, knowledge, and resources needed to carry out the proposed research as a project director or principal investigator (PD/PI).. Next deadline: 8 Dec 2026 (new applications). Official call: https://www.grants.gov/search-results-detail/356163 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-026 GG-PAR-25-026 Fri, 23 Oct 2026 08:00:00 +0000 This funding opportunity supports investigator-initiated, Phase I clinical trials and final stage preclinical activities for diagnostic and therapeutic interventions targeting heart, lung, blood, and sleep disorders. Funded projects will utilize a bi-phasic, milestone-driven R61/R33 mechanism to support both start-up and execution phases. Eligible applicants include higher education institutions, non-profits, for-profit organizations, and government entities based in the United States and its territories. Programme: National Heart, Lung, and Blood Institute (NHLBI). Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 3 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357543 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-DA-28-011 GG-RFA-DA-28-011 Thu, 22 Oct 2026 08:00:00 +0000 This funding opportunity aims to renew the Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) research network, supporting individual research projects coordinated by a central center. The goal is to test improved approaches for individuals suffering from both chronic pain and opioid use disorder to enhance health system care delivery. Eligible applicants include domestic and foreign institutions, higher education, non-profits, tribal governments, and other specified organizations. Programme: NIH HEAL Initiative. Eligible countries: Coming soon: published with the full call. Deadline: 26 Jan 2027. Official call: https://www.grants.gov/search-results-detail/360048 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-124 GG-PAR-25-124 Thu, 22 Oct 2026 08:00:00 +0000 The NCMRR Early Career Research Award supports rehabilitation scientists in establishing independent research careers by funding basic or clinical research projects. The aim is to collect preliminary data for a subsequent R01 application. Eligible applicant organizations include higher education institutions, nonprofits, for-profit organizations, governments, and foreign organizations. Early-stage investigators who are no more than 8 years past their terminal degree may apply as lead investigators. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Must be an independent investigator, no more than 8 years beyond the date their terminal academic degree was awarded. Not a postdoctoral fellow at submission.. Next deadline: 16 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357206 https://clinical-chaos-dsv.pages.dev/calls#c-WEB-6768384ca0cb WEB-6768384ca0cb Thu, 22 Oct 2026 08:00:00 +0000 This funding initiative accelerates Parkinson’s disease therapy development by funding pre-clinical and clinical development of disease-modifying or symptomatic interventions, as well as biomarker tools. Funding ranges from $250,000 to upwards of $5M for 1 to 3 years. The call is open to industry, academic/industry partnerships, and academic-led projects in certain cases. Applications follow a two-stage process with rolling pre-proposals and full proposals submitted by invitation. Programme: Parkinson's Disease Therapeutics Pipeline Program. Eligible countries: Not stated in the official text: check the call. Who can lead: Open to industry, academic/industry partnerships, and—in certain cases—academic-led projects.. Stage 1 deadline: 30 Oct 2026 (two-stage call). Official call: https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program https://clinical-chaos-dsv.pages.dev/calls#c-WEB-00773cbd93aa WEB-00773cbd93aa Thu, 22 Oct 2026 08:00:00 +0000 This funding program aims to support early career investigators whose Alzheimer's, Parkinson's, and related neurodegenerative research projects have been disrupted by changes or challenges in U.S. federal research funding. It funds salary and direct costs for projects facing delays, termination, priority misalignment, or funding gaps. Principal investigators must be early-stage investigators under NIH guidelines or within 7 years of their ESI designation, and host institutions must provide cost-sharing. Programme: Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN). Eligible countries: Not stated in the official text: check the call. Who can lead: All Principal Investigators must be an early-stage investigator under the NIH guidelines or within 7 years of their ESI designation.. Next deadline: 30 Oct 2026 (new applications). Official call: https://www.michaeljfox.org/grant/bridge-funding-disrupted-neurodegenerative-research-grant-program-bfdn-powering-next https://clinical-chaos-dsv.pages.dev/calls#c-EU-HORIZON-HLTH-2027-02-DISEASE-14-two-stage EU-HORIZON-HLTH-2027-02-DISEASE-14-two-stage Thu, 22 Oct 2026 08:00:00 +0000 This Horizon Europe call aims to support early-stage clinical trials evaluating the safety and efficacy of innovative, multi-disciplinary therapeutic interventions combined with complementary approaches for neurodegenerative diseases. Funded projects should improve patient quality of life, utilise health data according to FAIR principles, engage relevant stakeholders including patients, and leverage research infrastructures. Eligible applicants include international consortia composed of legal entities such as universities, clinical centres, and SMEs established in EU Member States or Associated Countries. Programme: Horizon Europe. Eligible countries: EU Member States and associated countries. Stage 1 deadline: 17 Feb 2027 (two-stage call). Official call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-02-DISEASE-14-two-stage https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526PRPEIRA GG-HT942526PRPEIRA Thu, 22 Oct 2026 08:00:00 +0000 The Early Investigator Research Award supports early-career investigators in conducting innovative Parkinson's disease research. It offers two funding levels: Level 1 for fellows requiring a mentor, and Level 2 for early-career independent investigators requiring preliminary data. Eligible applicants include domestic and foreign public, private, for-profit, and nonprofit organizations. Proposed research must address specific Parkinson's disease focus areas and benefit military and civilian populations. Clinical trials are not allowed. Programme: CDMRP – Parkinson’s Research Program (PRP). Eligible countries: Any country. Who can lead: Postdoctoral fellows, clinical fellows, or independent investigators within 10 years of advanced degree or residency training completion, or equivalent.. Deadline: 6 Nov 2026. Official call: https://www.grants.gov/search-results-detail/362866 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526PRPIIRA GG-HT942526PRPIIRA Thu, 22 Oct 2026 08:00:00 +0000 The Investigator-Initiated Research Award supports highly rigorous, multidisciplinary, high-impact research projects addressing Parkinson's disease across basic science to clinical trials. Funded research must target at least one specific FY26 Parkinson's Research Program focus area and require preliminary data. Independent investigators at all academic levels affiliated with eligible domestic or foreign organizations can apply, with total costs capped at $2 million over a maximum three-year performance period. Programme: CDMRP – Parkinson’s Research Program (PRP). Eligible countries: Any country. Who can lead: Independent investigators at all academic levels, or equivalent, affiliated with an eligible organization, regardless of ethnicity, nationality or citizenship s. Deadline: 6 Nov 2026. Official call: https://www.grants.gov/search-results-detail/362868 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526SCIRPTRA GG-HT942526SCIRPTRA Thu, 22 Oct 2026 08:00:00 +0000 The fiscal year 2026 Spinal Cord Injury Research Program Translational Research Award supports translational research that will accelerate the movement of promising ideas in spinal cord injury research into clinical applications. The call funds preclinical evaluations, clinical studies, and pilot trials addressing acute injury intervention, secondary health effects, psychosocial well-being, or rehabilitation. Eligible applicants include domestic and foreign, for-profit and nonprofit, public and private organizations. Proposals must name at least one spinal cord injury community partner. Programme: Defense Health Agency Spinal Cord Injury Research Program. Eligible countries: Any country. Who can lead: Independent investigators at all career levels can apply as Single PI. For Early-Career Partnership, at least one PI must be within 7 years of first faculty app. Stage 1 deadline: 12 Nov 2026 (two-stage call). Official call: https://www.grants.gov/search-results-detail/362222 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526SCIRPCTA GG-HT942526SCIRPCTA Thu, 22 Oct 2026 08:00:00 +0000 The fiscal year 2026 Spinal Cord Injury Research Program Clinical Trial Award supports the rapid implementation of clinical trials to significantly impact the treatment or management of spinal cord injury. Funding is available for single or partnering principal investigators, requiring at least two spinal cord community partners. Extramural and intramural organizations worldwide, including foreign and domestic, for-profit and nonprofit, are eligible to apply. Programme: CDMRP – Spinal Cord Injury Research Program (SCIRP). Eligible countries: Any country. Who can lead: Independent investigators at all career levels. For the partnership option, at least one PI must be an early-career investigator as specified.. Deadline: 12 Nov 2026. Official call: https://www.grants.gov/search-results-detail/362224 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526SCIRPCTRA GG-HT942526SCIRPCTRA Thu, 22 Oct 2026 08:00:00 +0000 The fiscal year 2026 Spinal Cord Injury Research Program Clinical Translation Research Award supports high-impact clinical research and clinical trials requiring preliminary studies to prepare for larger-scale implementation. The funding aims to accelerate the translation of interventions into clinical use and identify optimal diagnostic and treatment options. Eligible applicants include domestic and foreign organizations, and the call features an early-career partnership option and a requirement for community collaboration. Programme: CDMRP – Spinal Cord Injury Research Program (SCIRP). Eligible countries: Any country. Who can lead: Independent investigators at all career levels. For the Early-Career Partnership Option, at least one PI must be an early-career investigator.. Stage 1 deadline: 12 Nov 2026 (two-stage call). Official call: https://www.grants.gov/search-results-detail/362225 https://clinical-chaos-dsv.pages.dev/calls#c-GG-HT942526SCIRPIIRA GG-HT942526SCIRPIIRA Thu, 22 Oct 2026 08:00:00 +0000 The fiscal year 2026 Spinal Cord Injury Research Program Investigator-Initiated Research Award supports studies with the potential to contribute significantly to spinal cord injury research, patient care, and quality of life. It funds basic through translational science addressing specific programmatic goals. Eligible applicants include domestic and foreign organizations, both for-profit and non-profit. Independent investigators at all career levels may apply, with an optional early-career partnership pathway. Programme: CDMRP – Spinal Cord Injury Research Program (SCIRP). Eligible countries: Any country. Who can lead: Independent investigators at all career levels. For the Early-Career Partnership Option, at least one PI must be an early-career investigator.. Deadline: 12 Nov 2026. Official call: https://www.grants.gov/search-results-detail/362226 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PD-26-369Y GG-PD-26-369Y Thu, 22 Oct 2026 08:00:00 +0000 The Engineering Biological and Biomedical Systems program expands our understanding of biological and physiological systems to improve human health. It supports fundamental engineering research combining mechanistic insights with experimental and computational techniques to develop platforms, devices, tissues, and processes. Eligible applicants include a wide range of entities as specified by the funding agency, focusing on foundational discoveries rather than clinical trials or commercialization. Programme: U.S. National Science Foundation. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/362062 https://clinical-chaos-dsv.pages.dev/calls#c-GG-FOR-FD-25-001 GG-FOR-FD-25-001 Thu, 22 Oct 2026 08:00:00 +0000 This funding opportunity aims to support clinical trials evaluating the efficacy and safety of products to address unmet medical needs in rare neurodegenerative diseases for both children and adults. Funded through the R01 mechanism by the Food and Drug Administration, the initiative seeks to increase approved treatments and have a broad, positive impact on rare disease drug development. Eligible applicants include a wide variety of organizational types such as educational institutions, nonprofits, and for-profit entities. Programme: Food and Drug Administration. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/356054 https://clinical-chaos-dsv.pages.dev/calls#c-GG-FOR-FD-25-006 GG-FOR-FD-25-006 Thu, 22 Oct 2026 08:00:00 +0000 This funding opportunity supports studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. The initiative aims to address critical knowledge gaps, make a significant impact on rare neurodegenerative diseases, and inform current or future product development. Various entity types, including governments, educational institutions, nonprofits, and for-profit organizations, are eligible to apply. Programme: Food and Drug Administration. Eligible countries: Not stated in the official text: check the call. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/356046 https://clinical-chaos-dsv.pages.dev/calls#c-GG-RFA-NS-26-001 GG-RFA-NS-26-001 Thu, 22 Oct 2026 08:00:00 +0000 This funding opportunity solicits applications to conduct scientific research utilizing data from expanded access for investigational drugs or biological products. The research targets intermediate size populations of patients with amyotrophic lateral sclerosis who are ineligible for ongoing clinical trials. Eligible applicants are clinical trial sites participating in specific phase 2/3 or phase 3 efficacy clinical trials supported by an FDA-designated small business sponsor. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial supported by an FDA-designated small busines. Deadline: 10 Nov 2026. Official call: https://www.grants.gov/search-results-detail/360400 https://clinical-chaos-dsv.pages.dev/calls#c-WEB-14a8635c6be7 WEB-14a8635c6be7 Thu, 22 Oct 2026 08:00:00 +0000 The Foundation for Physical Therapy Research offers scholarships supporting licensed physical therapists and physical therapist assistants who are APTA members and pursuing an academic doctoral degree with the intent to pursue a research career in physical therapy. The call provides funding for two phases: pre-candidates receive annual awards of $7,500 for coursework, while doctoral candidates receive $15,000 annually for the candidacy phase. Programme: Promotion of Doctoral Studies Scholarships. Eligible countries: Not stated in the official text: check the call. Who can lead: Licensed physical therapists and physical therapist assistants who are APTA members pursuing a PhD, EdD, DSc, or other academic doctoral degrees.. Deadline: 20 Jan 2027. Official call: https://foundation4pt.org/foundation-funding-opportunities/scholarships/ https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-24-321 GG-PAR-24-321 Thu, 22 Oct 2026 08:00:00 +0000 The National Institute on Aging offers support for established investigators to enhance aging and Alzheimer's Disease or related dementias research and educational capacity within their academic institution. The award funds research and educational infrastructure, mentorship, and career development activities such as courses, pilot funding, and travel awards. Applicants must be US-based established investigators holding a doctoral degree and a named PD/PI role on an active R01 or equivalent NIA grant. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Next deadline: 12 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/357000 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-25-024 GG-PAR-25-024 Thu, 22 Oct 2026 08:00:00 +0000 This NIH funding opportunity promotes the discovery and development of candidate biomarkers or composite biomarkers for neurological and neuromuscular disorders. The phased R61/R33 mechanism supports initial proof-of-concept studies and preliminary clinical validation to ensure biomarkers are fit for use in clinical trials or clinical practice. Eligible applicant organizations include domestic U.S. higher education institutions, nonprofits, for-profit entities, and government bodies. Foreign entities are not eligible to apply. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).. Next deadline: 22 Feb 2027 (new applications). Official call: https://www.grants.gov/search-results-detail/356874 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-096 GG-PAR-27-096 Thu, 22 Oct 2026 08:00:00 +0000 The GEMSSTAR program aims to support early-career clinician-scientists in medical or surgical specialties to launch research careers focused on aging or geriatrics. It funds transdisciplinary pilot projects and professional development plans within supportive research environments. Only U.S.-based organizations are eligible to apply, as foreign organizations and foreign subawards are strictly excluded from this funding opportunity. Programme: NIH – US National Institutes of Health. Eligible countries: United States only (foreign organisations not eligible). Who can lead: Early-career clinician-scientists trained in medical or surgical specialties.. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/359940 https://clinical-chaos-dsv.pages.dev/calls#c-GG-PAR-27-065 GG-PAR-27-065 Thu, 22 Oct 2026 08:00:00 +0000 This funding opportunity invites investigator-initiated clinical trials addressing neurological diseases and disorders within the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Supported projects include early- and middle-phase exploratory clinical trials as well as later-phase confirmatory Phase 3 or comparative effectiveness trials involving small molecules, biologics, devices, and behavioral or rehabilitation therapies across the lifespan. Various domestic and foreign organizational types are eligible to apply. Programme: NIH – US National Institutes of Health. Eligible countries: Any country (non-US organisations eligible). Who can lead: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.. Deadline: see the official call. Official call: https://www.grants.gov/search-results-detail/360404